Slide 1: Investor Presentation – Q3 FY23
Investor Presentation – Q3 FY23 August 11, 2023
Slide 2: Caution Regarding Forward Looking Statements
Caution Regarding Forward Looking Statements Certain information included in this document is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally ac
Slide 3: Q3-23 Consolidated Results
Q3-23 Consolidated Results $131M $1.1B 11% -% Gross New Contract Signings Backlog Organic Growth Acquisitive Growth Revenues Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $) (in millions of $, except margin) (in millions of $, except margin) 169 167 60 40.0% 161 52 51 20.0 19.1 150 14
Slide 4: Q3-23 ITCS
Q3-23 ITCS $53M $100M -6% -% Gross New Contract Signings Backlog Organic Growth Acquisitive Growth Revenues Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $, except margin) (in millions of $, except margin) (in millions of $) 30 65.0% 14.0 35.0% 12.4 69 25.1 60.0% 25 12.0 30.0% 55.0% 1
Slide 5: Q3-23 Health
Q3-23 Health $27M $634M 23% -% Gross New Contract Signings Backlog Organic Growth Acquisitive Growth Revenues Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $, except margin) (in millions of $, except margin) (in millions of $) 10.0 40.0% 35.0% 49 14.0 13.4 9.0 9.0 44 30.0% 40 40 12.0
Slide 6: Q3-23 Advanced Technologies
Q3-23 Advanced Technologies $50M $142M 14% -% Gross New Contract Signings Backlog Organic Growth Acquisitive Growth Gross Profit & Margin Adj. EBITDA1 & Margin1 Revenues (in millions of $, except margin) (in millions of $, except margin) (in millions of $) 15.6 8.0 50.0% 47 45 16 7.1 13.7 7.0 45.0%
Slide 7: Q3-23 Learning
Q3-23 Learning $1M $269M 20% -% Gross New Contract Signings Backlog Organic Growth Acquisitive Growth Gross Profit & Margin Adj. EBITDA1 & Margin1 Revenues (in millions of $, except margin) (in millions of $) (in millions of $, except margin) 6.0 40.0% 5.4 29 9.0 8.2 32.0% 27 26 8.0 5.0 22 6.6 6.6 3
Slide 8: Q3-23 – Cash Flow
Q3-23 – Cash Flow Operating Free Cash Flow (OCFC)1&2&3 Working Capital Adj. EBITDA2 (in millions of $, except margin) (in millions of $) (in millions of $) 16.0 14.1 120% ($6M) 19.1 14.0 12.1 16.1 16.8 12.0 10.7 11.3 100% 12.4 10.2 14.3 14.5 85% 8.0 10.0 78% 80% 74% 8.0 64% 60% 63% 6.0 40% Q3-22 Q4-
Slide 9: Q3-23 – Capital Deployment
Q3-23 – Capital Deployment Acquisitions Dividends Capex1 (in millions of $) (in millions of $) (in millions of $) +$6M 6 3 3 3 3 3 3 4 2 2 2 3 3 1 0 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 1) Capex = Equipment and application software + Capitalized R
Slide 10: Q3-23 - Balance Sheet
Q3-23- Balance Sheet Total Debt Cash & Cash Equivalents Net Liquidity (in millions of $) (in millions of $) (in millions of $) 8 8 8 58 130 126 124 115 121 51 43 46 41 0 0 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 1) Net Liquidity= Unused portion of cr
Slide 11: FY23 – Updated Guidance
FY23 – Updated Guidance Revenues Adj. EBITDA1 Adj. Net Profit1 (in millions of $) (in millions of $) (in millions of $) 630-680 582 518 66 60-65 44 36-40 432 52 37 343 37 24 27 19 2019 2020 2021 2022 2023E 2019 2020 2021 2022 2023E 2019 2020 2021 2022 2023E 1) This is a non-GAAP measure. Please refe
Slide 12: Concluding Remarks
Acted quickly and decisively to adjust our business FY23 will be the 6" consecutive year of record revenues and gross profit The cost reduction measures will restore EBITDA levels in-line with recent performance as we enter FY24 FY24 expected to be another record year: = Expected cost savings of $8M
Slide 13: Question Period
Question Period Kevin Ford Patrick Houston Jennifer McCaughey CEO CFO & Corporate Secretary Director, Investor Relations
Slide 14: Thank you
See CALIAN . Thank you ir@calian.com
Slide 15: Reconciliation of Non-GAAP Measures – Adj. EBITDA
Reconciliation of Non-GAAP Measures – Adj. EBITDA (in thousands of $) Three months ended Nine months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net profit $4,673 $6,836 $13,766 $12,409 Depreciation of equipment and application software 2,361 2,237 6,910 4,666 Depreciation of right
Slide 16: Reconciliation of Non-GAAP Measures – Adj. Net Profit & Adj. EPS
Reconciliation of Non-GAAP Measures – Adj. Net Profit & Adj. EPS (in thousands of $, except per share amounts) Three months ended Nine months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Net Profit $4,673 $6,836 $13,766 $12,409 Changes in fair value related to contingent earn-out 13
Slide 17: Reconciliation of Non-GAAP Measures – Operating Free Cash Flow
Reconciliation of Non-GAAP Measures – Operating Free Cash Flow (in thousands of $, except per share amounts) Three months ended Nine months ended June 30, 2023 June 30, 2022 June 30, 2023 June 30, 2022 Cash flows generated from operating activities $2,545 $19,775 $34,071 $43,153 Capitalized research